-
Dr. Conconi at ESMO 2024: Charting the Course for Hematologic Malignancies Treatment
The 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) was recently held in Barcelona, Spain. As one of the top international conferences in the field of oncology, it gathered experts and scholars from around the world to share the latest research findings and explore future development directions. During this conference, several landmark…
-
ILCA 2024 Reveals: Sorafenib-Toripalimab and Anlotinib-Sintilimab Combos Yield Unprecedented Results in Liver Cancer
1. Two Studies Presented at ILCA Oncology Frontier: Professor Yang, you presented two studies at this year’s ILCA conference. Could you briefly introduce the key findings of each study? Professor…
-
CSCO 2024丨Dr. Hui Zhou: Challenges and Advances in Lymphoma Diagnosis and Treatment, from Standardization to Innovation
From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and 2024 CSCO Annual Meeting, hosted by the Chinese Society of Clinical Oncology (CSCO) and Beijing HopeRun…
-
Groundbreaking Honors at ILCA 2024: Celebrating Liver Cancer Research Milestones
The 2024 International Liver Cancer Association (ILCA) Conference recently held its highly anticipated awards ceremony in Rio de Janeiro, Brazil. This event attracted attention from liver cancer researchers worldwide, recognizing those who made significant contributions to the field over the past year. The ceremony aimed to further promote global collaboration and innovation in liver cancer…
-
IMS 2024丨Dr. Juan Li’s Team: Tandem ASCT as a Potentially Effective Strategy for High-Risk MM Patients with Dual Hits of 1q21 Amplification and t(4;14)
From September 25 to 28, 2024, the 21st International Myeloma Society (IMS) Annual Meeting was held in Rio de Janeiro, Brazil. At this prestigious conference, the research led by Dr. Juan Li from The First Affiliated Hospital of Sun Yat-sen University in China was selected for poster presentation. The study suggests that for high-risk multiple…
-
Advancing the Field: Dr. Pei Dong Discusses Groundbreaking Neoadjuvant Therapies for Renal Cancer at CSCO 2024
Surgery is a fundamental treatment for renal cancer, particularly for patients with stage I and II cancers, where surgery can cure the majority of cases and ensure long-term survival. At the 2024 CSCO Annual Meeting, Urology Frontier invited Dr. Pei Dong from Sun Yat-sen University Cancer Center to discuss this year’s key updates in the…
-
CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development
From September 25 to 29, 2024, the 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Xiamen. Themed Patient-Centered, Sharing the Future, the conference brought together major research advancements and developments from both domestic and international spheres. Over the past two decades, CSCO has been a continuous leader in…
-
Decoding Gene Silence: Nobel Honors Pioneers of microRNA in Blood Cancer Therapies
The 2024 Nobel Prize in Physiology or Medicine has once again brought the spotlight onto the field of gene regulation. This year, American scientists Victor Ambros and Gary Ruvkun were honored with the prestigious award for their pioneering research on microRNA and its role in post-transcriptional gene regulation. Their groundbreaking discoveries not only opened new…
Connecting Medical Expertise through Media